5T4 (oncofetal antigen) |
MEDI0641 |
tissue microarray, HNSCC cells (UM-SCC-11B, UM-SCC-22B), patient-derived xenograft (PDX) model |
Reduction of CSC fraction, tumor regression |
[186] |
Bmi1/AP-1 |
PTC-209 |
BmiCreER; RosatdTomato mice |
cisplatin plus PTC-209 potently eradicates Bmi1+ CSCs and inhibits tumor progression |
[80] |
FGF |
BGJ398 |
HNSCC cell lines |
decreased ALDHhighCD44high, sensitization to cisplatin |
[189] |
Porcupine (PORCN) (Wnt signaling) |
LGK974 |
HNSCC HN30 cell line |
High response in HNSCC with Notch loss of function mutation |
[190] |
ALDH1 |
Alda-89, Aldi-6 |
HNSCC cells, xenograft model |
Combination with cisplatin enhanced tumor cell death and reduced tumor growth |
[188] |
CD44 |
Radionuclide 186Re-cmAb (U36) |
Patients with Squamous Cell Carcinoma of the Head and Neck |
Dose-limiting myelotoxicity, reduction in tumor size |
[191] |
CD44v6 |
Anti-CD44v6 antibody BIWA- IRDye800CW and -Indium-111 |
Fluorescence-guided surgery, locally invasive xenograft model |
Detection of tumor regions and invasive zones |
[192] |
cMET/FZD8 |
PF-2341066 |
HNSCC patient-derived xenograft (PDX) |
Reduced sphere formation, tumor initiation and metastatic spread |
[187] |